Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 3/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1565617 | 0.93 | LDHA (0.63) | LDHAPPARGKDM4EALDH1A1CNR2 | |
| SCHEMBL21881586 | 0.87 | KDM4E (0.55) | PPARGKDM4EALDH1A1CHRM1MEN1 | |
| SCHEMBL660871 | 0.87 | KDM4E (0.55) | PPARGKDM4EALDH1A1CHRM1MEN1 | |
| SCHEMBL13324879 | 0.87 | KDM4E (0.55) | PPARGKDM4EALDH1A1CHRM1MEN1 | |
| Hydrogen Sulfide SCHEMBL28780976 | 0.85 | KDM4E (0.54) | PPARGKDM4EALDH1A1CHRM1MEN1 | |
| SCHEMBL1565656 | 0.85 | LDHA (0.54) | LDHAPPARGKDM4EALDH1A1KEAP1 | |
| SCHEMBL1566701 | 0.85 | LDHA (0.54) | LDHAPPARGKDM4EALDH1A1CYP1A2 | |
| SCHEMBL2662172 | 0.85 | LDHA (0.54) | LDHAPPARGKDM4EALDH1A1CYP1A2 | |
| SCHEMBL933549 | 0.85 | PPARG (0.58) | LDHAPPARGMEN1KMT2ACNR1 | |
| SCHEMBL11568688 | 0.84 | PPARG (0.54) | PPARGKDM4EALDH1A1CHRM1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206128-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206128-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206128-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20140288123-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2014-09-25 | — | — | US | disclosed |
| EP-2780014-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013075083-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2013-05-23 | — | — | WO | disclosed |
| EP-2305648-A1 | Amide derivatives useful as glucokinase activators | Novo Nordisk A/S (DK) | 2011-04-06 | — | — | EP | disclosed |
| EP-1458382-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| US-20030171411-A1 | Amide derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2003-09-11 | — | — | US | disclosed |
| EP-1336607-A1 | Amide derivatives as glucokinase activators | NOVO NORDISK A/S (DK) | 2003-08-20 | — | — | EP | disclosed |
| WO-2003055482-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288123-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TET1, TET3, EHMT2 | LDHA 3267/4885PPARG 3383/4885KDM4E 76/4885 |
| US-20030171411-A1 | Amide derivatives as therapeutic agents | GK, GCKR, GCK | LDHA 565/4885PPARG 75/4885KDM4E 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.